Cepheid provides molecular diagnostic testing for various health conditions, including infectious diseases and oncology. It offers diagnostic systems and services to healthcare professionals.

Cepheid

Advanced Bionics designs and manufactures cochlear implants and hearing technology, self-described as providing solutions for individuals with hearing loss.

Advanced Bionics

B. Braun is a medical technology company that provides a range of products and services related to healthcare.

B. Braun

Danaher Corporation

Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid’s broad test portfolio spans respiratory infections, blood virology, women’s and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company’s solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit http://www.cepheid.com.

Cepheid is proud to be a part of Danaher. Danaher’s science and technology leadership puts Cepheid’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers.

Together with Danaher’s other businesses across Biotechnology, Diagnostics, and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

U.S. Department of Defense

U.S. Department of Health & Human Services

Biomedical Advanced Research and Development Authority (BARDA)

Wheatley Partners

Innogenetics

Accurate detection of GroupA Strep supports antimicrobial stewardship and may reduce the number of patients inappropriately prescribed antibiotics. #RespiratoryHealth #StrepA

Learn more: https://lnkd.in/eRXv7Qu6

Cepheid receives expanded FDA clearance with CLIA Waiver for Xpert® Xpress MVP. We are committed to providing expanded access to #WomensHealth and #SexualHealth with PCR testing at the POC. Read all about it:

https://ow.ly/RKQu50QsbNg

There are approximately 11,500 new cases of cervical cancer diagnosed in the U.S. annually.* #CervicalCancerAwareness #MolecularDiagnostics 

*https://ow.ly/u42E50Qrv0i

Learn more about our Women’s Health and other testing solutions: https://ow.ly/Uqun50Qrv0h

Today we are honored to launch a new collaboration with the Innovative Genomics Institute (IGI) to develop a gene-editing solution designed to be easily modified to address potentially hundreds of devastating illnesses.

The Danaher-IGI Beacon for CRISPR Cures will take a revolutionary approach to genomic medicine, aiming to use CRISPR-based gene editing to permanently address the genetic causes of rare diseases with a unified technological approach.

By combining the R&D and manufacturing talent, technology and expertise of several Danaher businesses with the complementary academic research strengths at the IGI, we are dedicated to delivering on the enormous therapeutic promise of CRISPR for patients. https://bit.ly/48K8YbA

Aldevron Beckman Coulter Life Sciences Cytiva Integrated DNA Technologies Leica Biosystems Leica Microsystems Jennifer Doudna Fyodor Urnov

Cepheid is committed to providing expanded access to women’s and #sexualhealth with PCR testing at the POC. We’re excited to introduce Xpert® Xpress MVP, a multiplex vaginal panel to aid in the diagnosis of Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis for use in near-patient settings, with results in as soon as 60 min. Learn more: https://ow.ly/yjUt50QnTr7

Happy New Year. We wish you a happy, healthy, and peaceful 2024.

Hosting the Mayor of Markham, Ontario, Frank Scarpitti, at Cepheid Canada this month was a pleasure. Thank you for sharing our passion for innovation and improving patient outcomes with real-time PCR. #BestTeamWins #Cepheid #MolecularDiagnostics #MultiplexPCR #LabInACartridge

Wishing you all the joys of the season and happiness throughout the coming year. Best wishes from your friends at Cepheid.

Metric
Company Name	Cepheid	Advanced Bionics	B. Braun
Symbol
MSH ID	COM:CEPHEID	COM:ADVANCEDBIONICS	COM:BBRAUN
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare Technology	Medical Devices	Medical Devices
Country	US	US	DE
Stage
Employee Count	4.86K
Website	cepheid.com	advancedbionics.com	bbraun.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	44.68
28-Day Growth Score	50.20
90-Day Growth Score	47.71
365-Day Growth Score	41.95

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:CEPHEID

Cepheid

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue